Vanderbilt University Medical Center
- Type
- Teaching hospital
- Where
- Nashville, TN
- Medicare CCN
- 440039
- Received
- $34,322,978 in 3,223 records, 2022 ($1,287,082 general, $33,035,896 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: Vanderbilt University Medical Center Fuzzy (name and state)
- Business registration: Vanderbilt University Medical Center Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER, INC. Fuzzy (name and state)
- Business registration: VANDERBILT UNIVERSITY MEDICAL CENTER, INC. Fuzzy (name and state)
- Nonprofit contractor: Vanderbilt University Medical Center Fuzzy (name and state)
- Plan sponsor: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Federal award recipient: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Lobbying client: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Lobbying registrant: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Nonprofit: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
- Trademark owner: VANDERBILT UNIVERSITY MEDICAL CENTER Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2022 | General payment | 329 | $1,287,082 |
| 2022 | Research payment | 2,894 | $33,035,896 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,894 | $33,035,896 |
| Grant | 73 | $549,879 |
| Space rental or facility fees (teaching hospital only) | 101 | $277,979 |
| Consulting Fee | 13 | $119,925 |
| Debt forgiveness | 7 | $84,573 |
| Long term medical supply or device loan | 6 | $62,513 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 77 | $61,720 |
| Gift | 7 | $42,311 |
| Royalty or License | 23 | $40,588 |
| Education | 15 | $36,608 |
| Charitable Contribution | 7 | $10,982 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | Merck Sharp & Dohme LLC | $641,159 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $272,337 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $224,629 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $167,289 | Research payment | Cash or cash equivalent | Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $95,393 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $40,300 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2022 |
| 2022-12-31 | Soleno Therapeutics, Inc. | $38,086 | Research payment | Cash or cash equivalent | An Open-Label, Long-Term Safety and Efficacy Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $35,086 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $34,386 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $26,224 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $26,064 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $26,064 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $23,516 | Research payment | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | ENDOTRONIX, INC. | $14,298 | Research payment | Cash or cash equivalent | CORDELLA PULOMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $14,236 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,915 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 2, Single-arm, Open-label Clinical Trial of Pembrolizumab Plus Lenvatinib in Participants with First-line Advanc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $13,064 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $12,106 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $11,516 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $11,282 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2022 |
| 2022-12-31 | ABBVIE INC. | $11,031 | Research payment | In-kind items and services | DURYSTA Drug, GLAUCOMA | Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $10,636 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $10,636 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,880 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $9,726 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-31 | Philips North America LLC | $9,300 | Long term medical supply or device loan | In-kind items and services | (2809) Trilogy 100 Device, Medical Device | 2022 | |
| 2022-12-31 | Genentech, Inc. | $7,778 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | MY PATHWAY | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,454 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $7,283 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,323 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab MK-3475 versus Placebo as A | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $6,243 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,886 | Research payment | In-kind items and services | Biological, CARDIOVASCULAR | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus P | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,862 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,860 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $5,860 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Adv | 2022 |
| 2022-12-31 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $5,693 | Research payment | Cash or cash equivalent | Healey Platform Trial | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,820 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | Boston Scientific Corporation | $4,806 | Research payment | Cash or cash equivalent | Farapulse Device, Structural Heart | ADVENT | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $4,023 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Bel | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,465 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiot | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $3,263 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2022 |
| 2022-12-31 | AstraZeneca Pharmaceuticals LP | $3,127 | Research payment | In-kind items and services | ENHERTU Biological, Oncology | A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator Choice Chemo | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,858 | Research payment | In-kind items and services | LYNPARZA Biological, ONCOLOGY | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,768 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | KARL STORZ Endoscopy-America | $2,719 | Research payment | In-kind items and services | A Prospective Single Center Study of the Effects of Modulating Music in the Operating Room | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,687 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-Label Phase 2 Study to Evaluate PT2977 For The Treatment of Von Hippel-Lindau Disease-Associated Renal Cell Carc | 2022 |
| 2022-12-31 | Linvatec Corporation | $2,553 | Long term medical supply or device loan | In-kind items and services | AIRSEAL Device, GENERAL SURGERY | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,523 | Research payment | In-kind items and services | ZINPLAVA Biological, INFECTIOUS DISEASE | Protocol Title A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Phar | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2,197 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2022 |
| 2022-12-31 | bioMerieux Inc | $2,091 | Research payment | Cash or cash equivalent | E0418 - ETEST_USA_VUMC_HUMPHRIES_IIR_2021 | 2022 | |
| 2022-12-31 | bioMerieux Inc | $2,091 | Research payment | Cash or cash equivalent | E0418 - ETEST_USA_VUMC_HUMPHRIES_IIR_2021 | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,910 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,840 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 Pembrolizumab in Children and Young Adults with Newly | 2022 |
| 2022-12-31 | ABBVIE INC. | $1,581 | Research payment | In-kind items and services | Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In | 2022 | |
| 2022-12-31 | ABBVIE INC. | $1,502 | Research payment | In-kind items and services | Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Pa | 2022 | |
| 2022-12-31 | KARL STORZ Endoscopy-America | $1,471 | Research payment | In-kind items and services | A Prospective Single Center Study of the Effects of Modulating Music in the Operating Room | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $1,176 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulato | 2022 |
| 2022-12-31 | ABBVIE INC. | $1,080 | Research payment | In-kind items and services | LINZESS Drug, GASTROENTEROLOGY | Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Cons | 2022 |
| 2022-12-31 | ABBVIE INC. | $948 | Research payment | In-kind items and services | A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Mu | 2022 | |
| 2022-12-31 | Merck Sharp & Dohme LLC | $450 | Research payment | In-kind items and services | VERQUVO Drug, CARDIOVASCULAR | A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical out | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $190 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized Phase 3 Study Evaluating Cystectomy with Perioperative Pembrolizumab and Cystectomy with Perioperative Enfo | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $149 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Neg | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $136 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $30 | Research payment | In-kind items and services | BRIDION Drug, NEUROSCIENCE | A Phase 4 Randomized, Active-Comparator Controlled Clinical Trial to Study the Safety of Sugammadex MK-8616 for the Reve | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $2 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | Phase 1b,2 study of immune and targeted combination therapies in participants with RCC | 2022 |
| 2022-12-31 | Merck Sharp & Dohme LLC | $0 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b,2 Study of Immune and Targeted Combination Therapies in Participants With RCC KEYMAKER-U03 Substudy 03B | 2022 |
| 2022-12-30 | Janssen Research & Development, LLC | $35,183 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2022 | |
| 2022-12-30 | bioMerieux Inc | $28,361 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-12-30 | ARGENX US, INC. | $40 | Research payment | In-kind items and services | A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and the Safety of | 2022 | |
| 2022-12-29 | ABBVIE INC. | $5,600 | Research payment | Cash or cash equivalent | CREON Drug, ENDOCRINOLOGY | A Study to Compare US Marketed Creon Manufactured With a Modernized Process at an Alternate Manufacturing Site and Manuf | 2022 |
| 2022-12-29 | Mirum Pharmaceuticals, Inc. | $3,613 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects with Progressive Familial Intrahepatic Cholestasi | 2022 | |
| 2022-12-29 | PFIZER INC. | $893 | Research payment | Cash or cash equivalent | A PHASE 2A DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF0 | 2022 | |
| 2022-12-28 | GE HEALTHCARE | $144,796 | Research payment | Cash or cash equivalent | DIGITAL PRECISION ONCOLOGY PROJECT | 2022 | |
| 2022-12-28 | bioMerieux Inc | $14,106 | Research payment | Cash or cash equivalent | E0443 - EPISEQ_USA_VUMC_HUMPHRIES_IIR_2021 | 2022 | |
| 2022-12-28 | bioMerieux Inc | $14,106 | Research payment | Cash or cash equivalent | E0443 - EPISEQ_USA_VUMC_HUMPHRIES_IIR_2021 | 2022 | |
| 2022-12-28 | Astute Medical, Inc. | $6,739 | Research payment | Cash or cash equivalent | NephroCheck Test Kit Device, Diagnostics | AST-132 Diamond | 2022 |
| 2022-12-28 | Astute Medical, Inc. | $2,358 | Research payment | Cash or cash equivalent | NephroCheck Test Kit Device, Diagnostics | AST-132 Diamond | 2022 |
| 2022-12-28 | Intercept Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-12-28 | Intercept Pharmaceuticals, Inc. | $2,000 | Research payment | Cash or cash equivalent | OCALIVA Drug, Hepatology / Gastroenterology | Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment (REGENERATE) | 2022 |
| 2022-12-28 | Aveo Pharmaceuticals, Inc. | $675 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-28 | Aveo Pharmaceuticals, Inc. | $675 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-28 | Aveo Pharmaceuticals, Inc. | $649 | Research payment | Cash or cash equivalent | FOTIVDA Drug, Oncology | TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivo | 2022 |
| 2022-12-28 | Takeda Pharmaceuticals U.S.A., Inc. | $499 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2022 | |
| 2022-12-27 | Takeda Pharmaceuticals U.S.A., Inc. | $15,835 | Research payment | Cash or cash equivalent | EXKIVITY Drug | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32 | 2022 |
| 2022-12-27 | Kite Pharma, Inc. | $12,699 | Research payment | Cash or cash equivalent | Tecartus Drug, CELLT | A Multicenter, Open-label Expanded Access Study of KTE-X19 in Subjects with B-Cell Malignancies | 2022 |
| 2022-12-27 | KARL STORZ Endoscopy-America | $3,600 | Research payment | Cash or cash equivalent | A Prospective Single Center Study of the Effects of Modulating Music in the Operating Room | 2022 | |
| 2022-12-27 | Takeda Pharmaceuticals U.S.A., Inc. | $1,613 | Research payment | Cash or cash equivalent | EXKIVITY Drug | A PHASE 1/2 STUDY OF THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF THE ORAL EGFR/HER2 INHIBITOR TAK-788 (AP32 | 2022 |
| 2022-12-26 | PFIZER INC. | $152,784 | Research payment | Cash or cash equivalent | DELINEATING AND REDUCING CANCER DISPARITIES IN AFRICAN ANCESTRY AA INDIVIDUALS A HOLISTIC ANALYSIS OF RACEDISAGGREGATED | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $7,757 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $7,757 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $5,240 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $3,190 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $1,615 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $1,615 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $1,007 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-26 | Astellas Pharma Inc | $1,007 | Research payment | Cash or cash equivalent | A Phase 1 Study of ASP3082 in Participants With Previously Treated Locally Advanced or Metastatic Solid Tumor Malignanci | 2022 | |
| 2022-12-23 | W. L. Gore & Associates, Inc. | $648 | Research payment | Cash or cash equivalent | Product in Development Device, Devices | Gore CARDIOFORM Septal Occluder and Antiplatelet Medical Management for the Reduction of Recurrent Stroke in Patients wi | 2022 |
| 2022-12-23 | MEDIVATION LLC. | $598 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2022 |
| 2022-12-23 | MEDIVATION LLC. | $290 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A PHASE 3 RANDOMIZED EFFICACY AND SAFETY STUDY OF ENZALUTAMIDE PLUS LEUPROLIDE ENZALUTAMIDE MONOTHERAPY AND PLACEBO PLUS | 2022 |
| 2022-12-23 | Janssen Research & Development, LLC | $194 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Po | 2022 |
| 2022-12-23 | Bio-Rad Laboratories, Inc. | $16 | Gift | In-kind items and services | BioPlex2200 Device, BioPlex | 2022 | |
| 2022-12-22 | Contego Medical, Inc | $7,000 | Research payment | Cash or cash equivalent | Neuroguard IEP Device, Cardiovascular | Performance II | 2022 |
| 2022-12-22 | Medtronic, Inc. | $3,500 | Research payment | Cash or cash equivalent | ACTIVA PC Device, Deep Brain Neurostimulation | Epilepsy Post-Approval St | 2022 |
| 2022-12-21 | Kite Pharma, Inc. | $38,960 | Research payment | Cash or cash equivalent | A PHASE 2 OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF AXICABTAGENE-CILOLEUCEL CONCOMITANT WITH P | 2022 | |
| 2022-12-21 | BeiGene USA, Inc. | $31,127 | Research payment | Cash or cash equivalent | Retrospective review of outcomes in patients receiving oral specialty therapy for the treatment of c | 2022 | |
| 2022-12-21 | Takeda Pharmaceuticals U.S.A., Inc. | $5,915 | Research payment | Cash or cash equivalent | ELAPRASE Biological, GENETIC DISEASE | AN OPEN-LABEL EXTENSION TO STUDY HGT-HIT-045 EVALUATING LONG-TERM SAFETY AND CLINICAL OUTCOMES OF INTRATHECAL ADMINISTRA | 2022 |
| 2022-12-21 | Novo Nordisk AS | $4,086 | Research payment | Cash or cash equivalent | NN7415-4307 | 2022 | |
| 2022-12-21 | Incyte Corporation | $3,662 | Research payment | Cash or cash equivalent | A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib | 2022 | |
| 2022-12-21 | Novo Nordisk AS | $2,534 | Research payment | Cash or cash equivalent | Rybelsus Drug, Diabetes | EX9924-4473 | 2022 |
| 2022-12-21 | Takeda Pharmaceuticals U.S.A., Inc. | $2,000 | Research payment | Cash or cash equivalent | GATTEX Drug, INTERNAL MEDICINE | A PROSPECTIVE, MULTI-CENTER REGISTRY FOR PATIENTS WITH SHORT BOWEL SYNDROME | 2022 |
| 2022-12-21 | Novo Nordisk AS | $1,500 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4533 | 2022 |
| 2022-12-21 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participant | 2022 | |
| 2022-12-21 | Travere Therapeutics, Inc. | $969 | Research payment | Cash or cash equivalent | Cholbam Drug, Hepatology | The Replace Registry | 2022 |
| 2022-12-21 | Incyte Corporation | $785 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participant | 2022 | |
| 2022-12-21 | Incyte Corporation | $675 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participant | 2022 | |
| 2022-12-21 | Incyte Corporation | $524 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participant | 2022 | |
| 2022-12-21 | Incyte Corporation | $487 | Research payment | Cash or cash equivalent | A Phase 1, Open-Label, Multicenter Study of INCA00186 as Monotherapy or in Combination With Immunotherapy in Participant | 2022 | |
| 2022-12-21 | Novo Nordisk AS | $388 | Research payment | Cash or cash equivalent | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-21 | Incyte Corporation | $323 | Research payment | Cash or cash equivalent | A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib | 2022 | |
| 2022-12-21 | Novo Nordisk AS | $150 | Research payment | Cash or cash equivalent | NN7415-4307 | 2022 | |
| 2022-12-20 | Bayer Healthcare Pharmaceuticals Inc. | $18,432 | Research payment | Cash or cash equivalent | Kerendia Drug, Cardio-renal | BAY94-8862, Finerenone Phase 3 in non-diabetic CKD | 2022 |
| 2022-12-20 | Genentech, Inc. | $12,808 | Research payment | Cash or cash equivalent | OCREVUS Biological, Immunology | ENSEMBLE | 2022 |
| 2022-12-20 | KYOWA KIRIN, INC. | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NOURIANZ Drug, Adenosine A2A Receptors | 2022 | |
| 2022-12-20 | E.R. Squibb & Sons, L.L.C. | $1,922 | Research payment | Cash or cash equivalent | PhIII Stage 3/4 Resectable Mel Adj Rela+Nivo vs Nivo - A Phase 3, Randomized, Double-blind Study of Adjuvant Immunothera | 2022 | |
| 2022-12-20 | Cumberland Pharmaceuticals, Inc. | $1,750 | Research payment | Cash or cash equivalent | ORAL IFETROBAN TO TREAT ASPIRIN EXACERBATED RESPIRATORY DISEASE (AERD) | 2022 | |
| 2022-12-20 | Takeda Pharmaceuticals U.S.A., Inc. | $1,275 | Research payment | Cash or cash equivalent | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EA | 2022 | |
| 2022-12-20 | Pharmacyclics LLC, an AbbVie Company | $1,000 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL???: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2022 |
| 2022-12-20 | Pharmacyclics LLC, an AbbVie Company | $250 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL???: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2022 |
| 2022-12-20 | Pharmacyclics LLC, an AbbVie Company | $250 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | informCLL???: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL) | 2022 |
| 2022-12-20 | E.R. Squibb & Sons, L.L.C. | $175 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF BMS-986036 (PEG-FGF2 | 2022 | |
| 2022-12-19 | Merck Sharp & Dohme LLC | $284,067 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan MK-6482, formerly PT2977 Monotherapy in Participants w | 2022 |
| 2022-12-19 | Merck Sharp & Dohme LLC | $159,156 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | A Phase 1 , Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan MK-6482 in Participants With Advance | 2022 |
| 2022-12-19 | Merck Sharp & Dohme LLC | $65,664 | Research payment | Cash or cash equivalent | WELIREG Drug, ONCOLOGY | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants with Advanced Renal Cell Carcinoma | 2022 |
| 2022-12-19 | Biogen, Inc. | $25,000 | Royalty or License | Cash or cash equivalent | 2022 | ||
| 2022-12-19 | Janssen Research & Development, LLC | $23,946 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Po | 2022 |
| 2022-12-19 | Biosense Webster, Inc. | $16,584 | Research payment | Cash or cash equivalent | Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI IRE Ablation System | 2022 | |
| 2022-12-19 | Janssen Research & Development, LLC | $4,661 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2022 | |
| 2022-12-19 | AERIN MEDICAL INC. | $4,576 | Research payment | Cash or cash equivalent | VIVAER STYLUS Device, EAR NOSE & THROAT | CTP 1125 - SWELL | 2022 |
| 2022-12-19 | Janssen Research & Development, LLC | $4,521 | Research payment | Cash or cash equivalent | A Phase 1b Study of Subcutaneous Daratumumab Regimens in Combination with Bispecific T Cell Redirection Antibodies for t | 2022 | |
| 2022-12-19 | Olympus America Inc. | $4,279 | Debt forgiveness | In-kind items and services | HD 3CMOS AUTOCLAVABLE CAMERA HEAD Device, Surgical Endoscopy | 2022 | |
| 2022-12-19 | AERIN MEDICAL INC. | $2,781 | Research payment | Cash or cash equivalent | RHINAER STYLUS Device, EAR NOSE & THROAT | CTP 1004 - RHINTRAC | 2022 |
| 2022-12-19 | Janssen Research & Development, LLC | $2,500 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction The | 2022 |
| 2022-12-19 | Boston Scientific Corporation | $1,721 | Research payment | Cash or cash equivalent | WATCHMAN Access System Device, STRUCTURAL HEART | CHAMPIONAF | 2022 |
| 2022-12-19 | Olympus America Inc. | $549 | Debt forgiveness | In-kind items and services | EVIS EXERA lll COLONOVIDEOSCOPE Device, Gastroenterology | 2022 | |
| 2022-12-19 | Pharmacyclics LLC, an AbbVie Company | $485 | Research payment | Cash or cash equivalent | IMBRUVICA Drug, ONCOLOGY | Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. | 2022 |
| 2022-12-19 | Medtronic, Inc. | $394 | Research payment | Cash or cash equivalent | INTERSTIM Device, Sacral Nerve Stimulation | ELITE | 2022 |
| 2022-12-19 | Olympus America Inc. | $326 | Debt forgiveness | In-kind items and services | HIGH DEFINITION LCD MONITOR Device, Gastroenterology | 2022 | |
| 2022-12-19 | Olympus America Inc. | $232 | Debt forgiveness | In-kind items and services | EVIS EXERA III GASTROINTESTINAL VIDEOSCOPE Device, Gastroenterology | 2022 | |
| 2022-12-17 | PFIZER INC. | $3,349 | Research payment | Cash or cash equivalent | BRAFTOVI Drug, ONCOLOGY | AN OPENLABEL MULTICENTER RANDOMIZED PHASE 3 STUDY OF FIRSTLINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY V | 2022 |
| 2022-12-16 | ACADIA Pharmaceuticals Inc | $20,634 | Research payment | Cash or cash equivalent | ACP-2566-009 | 2022 | |
| 2022-12-16 | ACADIA Pharmaceuticals Inc | $18,900 | Research payment | Cash or cash equivalent | ACP-2566-004 | 2022 | |
| 2022-12-16 | ACADIA Pharmaceuticals Inc | $10,624 | Research payment | Cash or cash equivalent | ACP-2566-005 | 2022 | |
| 2022-12-16 | BioMarin Pharmaceutical Inc. | $5,831 | Research payment | Cash or cash equivalent | A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children with Achondrop | 2022 | |
| 2022-12-16 | Genentech USA, Inc. | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Activase Biological, Metabolism & Primary Care | 2022 | |
| 2022-12-16 | Bayer Healthcare Pharmaceuticals Inc. | $1,845 | Research payment | Cash or cash equivalent | Vitrakvi Drug, Oncology | BAY2757556, open label basket trial | 2022 |
| 2022-12-16 | Bolton Medical Inc | $1,651 | Research payment | Cash or cash equivalent | RelayPro-A IP-0015-16 Device, Device | RelayPro-A IP-0015-16 | 2022 |
| 2022-12-16 | BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | $677 | Research payment | In-kind items and services | A Randomized Double-Blind Placebo-Controlled Parallel- Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Su | 2022 | |
| 2022-12-16 | ACADIA Pharmaceuticals Inc | $553 | Research payment | Cash or cash equivalent | ACP-2566-004 | 2022 | |
| 2022-12-16 | Genentech, Inc. | $446 | Research payment | Cash or cash equivalent | TNKase Biological, Metabolism & Primary Care | TENECTEPLASE IN STROKE PATIENTS BETWEEN 4 5 AND 24 HOURS | 2022 |
| 2022-12-16 | Novo Nordisk AS | $110 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-16 | EMD Millipore Corporation | $31 | Royalty or License | Cash or cash equivalent | Device, DIAGNOSTIC TESTING | 2022 | |
| 2022-12-15 | Medical Device Business Services, Inc. | $11,996 | Research payment | Cash or cash equivalent | TRUFILL Device, Neurovascular | A Prospective, Multi-Center, Randomized Controlled Pivotal Study to Evaluate the Safety and Effectiveness of TRUFILLn-BC | 2022 |
| 2022-12-15 | ABBVIE INC. | $8,860 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohnx27s Disease | 2022 |
| 2022-12-15 | Mirum Pharmaceuticals, Inc. | $8,116 | Research payment | Cash or cash equivalent | A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects with Progressive Familial Intrahepatic Cholestasi | 2022 | |
| 2022-12-15 | Hoffmann-La Roche Limited | $3,385 | Research payment | Cash or cash equivalent | Avastin Biological, BioOncology | MORPHEUS TNBC | 2022 |
| 2022-12-15 | ABBVIE INC. | $1,230 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Cr | 2022 |
| 2022-12-15 | Novo Nordisk AS | $15 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-15 | Novo Nordisk AS | $10 | Research payment | In-kind items and services | Ozempic Drug, Diabetes | NN9535-4321 | 2022 |
| 2022-12-14 | Bausch Health US, LLC | $19,900 | Research payment | Cash or cash equivalent | XIFAXAN Drug, Gastroenterology | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble | 2022 |
| 2022-12-14 | Genentech, Inc. | $896 | Research payment | Cash or cash equivalent | TECENTRIQ Biological, BioOncology | PHASE III STUDY IN ADJUVANT THERAPY IN RENAL CELL CARCINOMA PATIENTS | 2022 |
| 2022-12-14 | Chiesi USA, Inc. | $270 | Research payment | Cash or cash equivalent | PRO00038725 | 2022 | |
| 2022-12-14 | Exelixis Inc. | $133 | Research payment | Cash or cash equivalent | Cabometyx Drug, Oncology | A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus | 2022 |
| 2022-12-13 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | XARELTO Drug, Cardiovascular & Metabolism | A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events Hospitalization and Death in Me | 2022 |
| 2022-12-12 | Incyte Corporation | $282,419 | Research payment | Cash or cash equivalent | 2022 | ||
| 2022-12-12 | Kite Pharma, Inc. | $232,570 | Research payment | Cash or cash equivalent | ISR: WAVE-7 (Oluwole), Safety and Feasibility Study of Chimeric Antigen Receptor (CAR) T Cell Therapy with YESCARTA in t | 2022 | |
| 2022-12-12 | Edwards Lifesciences Corporation | $8,373 | Research payment | Cash or cash equivalent | EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) Device, Transcatheter Heart Valves | Evaluation of Transcatheter Aortic Replacement Compared to Surveillance for Patients with Asymptomatic Severe Aortic Ste | 2022 |
| 2022-12-12 | Gilead Sciences, Inc. | $3,036 | Research payment | Cash or cash equivalent | Sovaldi Drug, HCV | A Long Term Follow-up Registry for Pediatric Subjects Who Received Treatment in Gilead-Sponsored Chronic Hepatitis C Inf | 2022 |
| 2022-12-12 | Merz Pharmaceuticals, LLC | $1,982 | Research payment | Cash or cash equivalent | Xeomin Biological, Musculoskeletal | Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Period to Investigate | 2022 |
| 2022-12-12 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | STELARA Biological, Immunology | A Phase 3b Randomized Double blind Multi Center Study to Evaluate the Safety and Efficacy of Intravenous Reinduction The | 2022 |
| 2022-12-12 | Takeda Pharmaceuticals U.S.A., Inc. | $1,500 | Research payment | Cash or cash equivalent | A PHASE-III, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, INTERNATIONAL, MULTICENTRE STUDY TO ASSESS EF | 2022 | |
| 2022-12-12 | Incyte Corporation | $1,250 | Research payment | Cash or cash equivalent | The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes | 2022 | |
| 2022-12-12 | Medical Device Business Services, Inc. | $200 | Research payment | Cash or cash equivalent | DePuy Synthes Lower Extremity Shaft Nail Registry (RFN-Advanced Retrograde Femoral Nailing System/ TN-Advanced Tibial Na | 2022 | |
| 2022-12-10 | Incyte Corporation | $938 | Research payment | Cash or cash equivalent | A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib | 2022 | |
| 2022-12-10 | Incyte Corporation | $938 | Research payment | Cash or cash equivalent | A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib | 2022 | |
| 2022-12-09 | CSL Behring | $67,500 | Research payment | Cash or cash equivalent | Validation of Cutaneous Nerve Demyelination in the Diagnosis and Treatment of CIDP | 2022 | |
| 2022-12-09 | Incyte Corporation | $23,319 | Research payment | Cash or cash equivalent | A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib | 2022 |
The latest 200 records of 3,223.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Nashville-Davidson, TN, county Davidson County, TN, state Tennessee; placed by its city name.
| Measure | Place (city or town) Nashville-Davidson, TN | County Davidson County, TN | State Tennessee |
|---|---|---|---|
| Population B01003 | 690,130 | 715,388 | 7,066,383 |
| Population, 2020 census P1 | 689,447 | 715,884 | 6,910,840 |
| Median age B01002 | 34.5 | 34.6 | 38.9 |
| Under 18 B01001 | 20.7% | 20.7% | 22.2% |
| 65 and over B01001 | 12.7% | 12.9% | 17.1% |
| Households B11001 | 313,513 | 324,907 | 2,824,277 |
| Foreign born B05002 | 15.3% | 15.0% | 6.1% |
| Median household income B19013 | $77,371 | $77,853 | $69,595 |
| Median family income B19113 | $98,376 | $99,460 | $87,314 |
| Per capita income B19301 | $49,061 | $50,640 | $39,437 |
| Poverty rate B17001 | 14.1% | 13.9% | 13.8% |
| Unemployment rate B23025 | 4.5% | 4.5% | 4.7% |
| Civilian labor force B23025 | 407,433 | 421,061 | 3,527,571 |
| Mean commute (minutes) B08013 | 24.7 | 24.7 | 25.7 |
| Bachelor's degree or higher B15003 | 48.0% | 48.4% | 31.1% |
| Housing units B25001 | 344,794 | 357,113 | 3,143,670 |
| Owner-occupied B25003 | 52.4% | 52.8% | 66.9% |
| Renters B25003 | 47.6% | 47.2% | 33.1% |
| Median home value B25077 | $413,600 | $417,400 | $286,700 |
| Median gross rent B25064 | $1,586 | $1,582 | $1,189 |
| White, not Hispanic B03002 | 52.6% | 53.2% | 71.0% |
| Black B03002 | 24.5% | 24.3% | 15.4% |
| Hispanic or Latino B03002 | 14.1% | 13.9% | 7.4% |
| Asian B03002 | 3.5% | 3.4% | 1.9% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Nashville-Davidson, TN.
Comments